PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

Journal of Clinical Investigation

Volumn 128, Issue 2, 2018, Pages 580-588

  Tang, Haidong ^a   Liang, Yong ^b   Anders, Robert A ^c   Taube, Janis M ^c,d   Qiu, Xiangyan ^a   Mulgaonkar, Aditi ^e   Liu, Xin ^f   Harrington, Susan M ^f   Guo, Jingya ^b   Xin, Yangchun ^e   Xiong, Yahong ^g   Nham, Kien ^e   Silvers, William ^e   Hao, Guiyang ^e   Sun, Xiankai ^h   Chen, Mingyi ^a   Hannan, Raquibul ^e   Qiao, Jian ^a   Dong, Haidong ^f   Peng, Hua ^b   Fu, Yang Xin ^a,b,e   more..

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b INSTITUTE OF BIOPHYSICS   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Bloomberg Kimmel Institute of Cancer Immunotherapy   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

^h Advanced Imaging Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

A20 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL MIGRATION; COHORT ANALYSIS; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; DRUG MECHANISM; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HOST CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MC-38 CELL LINE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; WHOLE BODY PET; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CELL LINE; CELLULAR IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; B7-H1 ANTIGEN; CELL LINE; CELL LINE, TUMOR; FLOW CYTOMETRY; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID CELLS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85041490670     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI96061     Document Type: Article

References (35)

1. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. SciTranslMed. 2016;8(328):328rv4.
2. Topalian SL, et al. Safety, activity, and immune correlates of anti- PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
3. Brahmer JR, et al. Safety and activity of anti- PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465.
4. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 2013;19(5):1021–1034.
5. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc NatlAcadSciUSA. 2002;99(19):12293–12297.
6. Hirano F, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089–1096.
7. Taube JM, et al. Colocalization of inflammatory response with B7-h1 expression in human mela-nocytic lesions supports an adaptive resistance mechanism of immune escape. SciTranslMed. 2012;4(127):127ra37.
8. Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
9. Powles T, et al. MPDL3280A (anti- PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–562.
10. Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.
11. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580–6587.
12. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33(17):1974–1982.
13. Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory Pathways in Immunotherapy for Cancer. Annu Rev Immunol. 2016;34:539–573.
14. Blank C, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64(3):1140–1145.
15. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3-potential mechanisms of action. Nat Rev Immunol. 2015;15(1):45–56.
16. Nguyen DP, Thalmann GN. Contemporary update on neoadjuvant therapy for bladder cancer. Nat Rev Urol. 2017;14(6):348–358.
17. Tang H, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016;29(3):285–296.
18. Selby MJ, et al. Preclinical development of ipili-mumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS One. 2016;11(9):e0161779.
19. Chen L, Han X. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–3391.
20. Heskamp S, et al. Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti- PD-L1 antibodies. Cancer Res. 2015;75(14):2928–2936.
21. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol. 2015;33:23–35.
22. Curiel TJ, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562–567.
23. Herbst RS, et al. Predictive correlates of response to the anti- PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567.
24. Kleinovink JW, Marijt KA, Schoonderwoerd MJA, van Hall T, Ossendorp F, Fransen MF. PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. Oncoimmunology. 2017;6(4):e1294299.
25. Lau J, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8:14572.
26. Juneja VR, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214(4):895–904.
27. Noguchi T, et al. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. CancerImmunolRes. 2017;5(2):106–117.
28. Taube JM, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti- PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074.
29. Garber K. Predictive biomarkers for checkpoints, first tests approved. Nat Biotechnol. 2015;33(12):1217–1218.
30. Benci JL, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167(6):1540–1554.e12.
31. Tang H, Qiao J, Fu YX. Immunotherapy and tumor microenvironment. Cancer Lett. 2016;370(1):85–90.
32. Salmon H, et al. Expansion and activation of CD103 (+) Dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924–938.
33. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immuno-ther Cancer. 2014;2:3.
34. Chamoto K, et al. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci U S A. 2017;114(5):E761–E770.
35. Hao G, et al. Serial non-invasive assessment of antibody induced nephritis in mice using positron emission tomography. PLoS One. 2013;8(2):e57418.